3646 results for «2613»
3646 results
New insights into pharmacological treatment for STEMI
21 May 2026 – From EuroPCR 2026
This session presents the latest pharmacological advances in the treatment of ST-segment elevation myocardial infarction (STEMI). It covers safety data on ticagrelor monotherapy post-primary PCI, the impact of P2Y12 inhibitor pretreatment, effects of dapagliflozin on myocardial remodeling, and considerations for bleeding risk and vascular preparation strategies...
Diagnosis and management of INOCA and ANOCA
21 May 2026 – From EuroPCR 2026
This session focuses on the diagnosis and management of ischemia and angina with non-obstructive coronary arteries (INOCA and ANOCA). It presents safety data from coronary function testing, patient outcomes after comprehensive ischemia assessment, and endotype-specific treatment effects. Further topics include coronary sinus reducer therapy, the impact...
Challenges of multivessel disease in ACS
21 May 2026 – From EuroPCR 2026
Dedicated to the challenges of multivessel disease in acute coronary syndrome (ACS), this session explores strategies to identify culprit versus non-culprit lesions and plan multivessel revascularisation using physiology, intravascular imaging, and artificial intelligence. It further discusses the timing considerations for revascularisation, whether ad-hoc or staged, illustrated...
DCB: what we know and what we do not know
22 May 2026 – From EuroPCR 2026
This session provides a detailed update on drug-coated balloons (DCB) in interventional cardiology, covering the latest clinical data and trials. It identifies scenarios where DCB use is most effective and offers guidance on optimizing procedural techniques to enhance clinical outcomes.
First-in-human studies in cardiovascular devices: from first 10 patients to global innovation — How efficient early studies advance emerging technologies
20 May 2026 – From EuroPCR 2026
Understand the pivotal role of first-in-human studies in advancing cardiovascular device innovation through operational insights from early patient experiences. This session reviews cutting-edge technologies including percutaneous left ventricular assist devices, transcatheter leaflet augmentation, physiology-guided PCI, synchronized diaphragmatic stimulation, pulmonary artery denervation, and perspectives on translating early...
Left main interventions: pushing the boundaries
21 May 2026 – From EuroPCR 2026
Examine contemporary strategies for distal left main bifurcation disease treatment, including debates on complex bifurcation and high-risk PCI approaches. The session emphasizes the critical role of coronary imaging in guiding decision-making and showcases clinical cases illustrating management of left main interventions under challenging conditions.
Stentless PCI, DCB and BVS in complex scenarios
20 May 2026 – From EuroPCR 2026
This session explores the use of stentless percutaneous coronary interventions (PCI) employing drug-coated balloons (DCB) and bioresorbable scaffolds (BVS) in complex coronary scenarios. Through detailed case discussions, it addresses decision-making processes, technical considerations, and practical tips for successfully completing PCI without permanent stenting.
Adopting a step-by-step approach for successful redo TAVI
21 May 2026 – From EuroPCR 2026
This session outlines a systematic step-by-step approach for redo TAVI procedures, including detailed pre-procedural CT analysis. It addresses challenges associated with failing short and tall-frame valves, and discusses coronary protection and leaflet modification techniques critical for successful reinterventions.
Innovation in transcatheter mitral valve interventions
21 May 2026 – From EuroPCR 2026
This comprehensive session presents the latest innovations in transcatheter mitral valve interventions, highlighting cutting-edge devices and clinical experiences. Topics include early feasibility studies of novel hemivalve systems, first-in-human experiences with new mitral valve replacement technologies, advances in transcatheter edge-to-edge repair (TEER) with one-year outcome data, and...
DCB - Going beyond in-stent restenosis
20 May 2026 – From EuroPCR 2026
This session examines the expanding role of drug-coated balloons (DCB) beyond in-stent restenosis, including treatment of acute coronary syndromes, calcified lesions, and bifurcations. It reviews current evidence supporting DCB-based revascularization and outlines essential procedural steps to optimize outcomes.
Routine primary PCI: what can go wrong?
21 May 2026 – From EuroPCR 2026
This session offers an in-depth examination of potential complications during routine primary PCI, focusing on prevention and management strategies. Key learning points include understanding no-reflow phenomena, managing STEMI in post-CABG patients, and handling thrombus burden effectively. Real-world cases illustrate decision-making processes and therapeutic approaches to optimize...
New tools for risk stratification in STEMI
20 May 2026 – From EuroPCR 2026
This session highlights novel tools and scores for risk stratification in ST-elevation myocardial infarction (STEMI) patients. It covers prognostic indices such as the index of microcirculatory resistance, the PREDICT-STEMI score, thrombus characteristics, sex differences in outcomes, renal impairment impacts, and benefits of complete revascularization strategies.
Insight from recent evidence in coronary artery disease: value of DCB for de novo lesions (SELUTION) and imaging for left main PCI (OPTIMAL)
21 May 2026 – From EuroPCR 2026
This session reviews pivotal recent evidence impacting daily practice in coronary artery disease management. It discusses the role of drug-coated balloons (DCB) for de novo lesions as evaluated in the SELUTION trial and evaluates intracoronary imaging strategies for left main PCI as presented in the OPTIMAL...
Complications in coronary interventions
20 May 2026 – From EuroPCR 2026
This session reviews uncommon and challenging complications encountered during coronary interventions. Cases include brachial arteriovenous fistula following radial access, retained guidewires, coronary sinus perforation during device implantation, and complex atherectomy procedures, emphasizing preparedness and management strategies.
The structural bailout playbook: managing complications
21 May 2026 – From EuroPCR 2026
The session presents a practical structural bailout playbook focused on managing complex complications during structural heart interventions. It features challenging cases such as unusual atrial septal defect closure complications, navigation of a displaced patent ductus arteriosus stent in infants, percutaneous closure of mitral paravalvular leaks with...
Reliability and application of angio-based physiology in daily work
20 May 2026 – From EuroPCR 2026
This session evaluates the reliability and clinical application of angiography-based physiological assessments in daily practice. Topics include comparisons of angiography-derived microvascular resistance and flow metrics with invasive methods, reproducibility of quantitative flow ratio (QFR), and its correlation with symptom burden and other imaging modalities.
Revascularisation in patients with multivessel disease and severe left ventricular impairment
21 May 2026 – From EuroPCR 2026
This session focuses on revascularisation strategies for patients with multivessel coronary disease complicated by severe left ventricular impairment. It emphasizes patient selection criteria, the crucial role of the heart team in decision-making, and optimization of percutaneous revascularisation outcomes. The content includes comprehensive case presentations and discussions...
Challenges during PCI on bifurcation
20 May 2026 – From EuroPCR 2026
This session addresses the complexities of percutaneous coronary intervention (PCI) in bifurcation lesions. It discusses decision-making strategies, techniques to avoid implanting permanent devices, the use of IVUS-guided laser atherectomy for restenosis, and approaches to challenging double bifurcation lesions including drug-coated balloon therapy.
Advanced heart failure: left ventricular assist device as bridge to optimise guided-directed medical therapy
21 May 2026 – From EuroPCR 2026
This session explores advanced heart failure management with a focus on guided-directed medical therapy and the role of left ventricular assist devices (LVAD) as a bridge to therapy optimization. It discusses clinical, imaging, and biological parameters indicating LVAD use and highlights devices such as the Impella...
Optimal use of dedicated device for calcified lesions
20 May 2026 – From EuroPCR 2026
This session delves into the optimal utilization of dedicated devices for managing complex coronary calcification. Explore decision-making strategies involving orbital atherectomy and cutting balloon techniques, as well as advanced approaches like contact intravascular lithotripsy for stented calcified nodules. Additional focus is given to ablative and modifying...